The product described as Cefepime Hydrochloride with L-Arginine (sterile) Pharma Grade API for tablet, capsule, granule, and injection applications is a combined pharmaceutical ingredient consisting of cefepime hydrochloride monohydrate and L-arginine in a fixed ratio corresponding to the commercial parenteral reference formulation. In the reference presentation, 1.0 g cefepime base equivalent is combined with 725 mg L-arginine per vial. The product does not carry a proprietary model number; its identity is defined by the pharmacopoeial monograph name, the salt form, and the sterile, non-pyrogenic grade designation. Cefepime is a fourth-generation cephalosporin antibiotic whose zwitterionic structure enables rapid penetration through Gram-negative outer membrane porins. Without L-arginine, an aqueous solution of cefepime hydrochloride at 10 mg/mL exhibits a pH in the range 1.6–2.8; this acidic environment accelerates β-lactam hydrolysis and contributes to injection-site intolerance upon intramuscular or intravenous administration. The addition of L-arginine buffers the reconstituted solution to pH 4.0–6.0, measured by USP <791>, which is the range specified in the Cefepime for Injection monograph. This co-formulation reduces free-water-mediated degradation and allows the product to be presented as a lyophilized or dry powder fill in Type I glass vials.

Release specification parameters for the sterile API include appearance, identification, assay, pH, water content, bacterial endotoxins, sterility, particulate matter, residual solvents, and elemental impurities. The cefepime assay acceptance range in the current pharmacopoeial monograph is commonly 90.0%–105.0% on the dried basis; verification against the active USP monograph for Cefepime Hydrochloride is required for each lot. Water content is controlled by Karl Fischer USP <921> at not more than 3.5%, consistent with the theoretical hydrate stoichiometry of approximately 3.4% for the monohydrate salt. The endotoxin threshold is calculated by the dose-based formula in USP <85>: for a 2 g maximum bolus dose in a 70 kg patient with K = 5 EU/kg, the limit is 0.175 EU/mg. Sterility testing per USP <71> uses direct inoculation into soybean-casein digest medium and fluid thioglycollate medium with incubation at 20–25°C and 30–35°C for 14 days. Residual solvents are limited according to ICH Q3C Table 1 and Table 2 classifications; Class 1 solvents must be absent, Class 2 solvents are controlled to their permitted daily exposure limits, and Class 3 solvents are limited to 0.5% total. Elemental impurity control follows ICH Q3D; for parenteral products, Class 1 limits are Cd ≤ 2 ppm, Pb ≤ 5 ppm, As ≤ 15 ppm, and Hg ≤ 3 ppm, while Class 2A elements Co and Ni are controlled at their permitted daily exposure-derived concentrations.

What Reconstitution pH Envelope Prevents Beta-Lactam Hydrolysis in Lyophilized Vials?

Published stability data for cefepime hydrochloride indicate that aqueous degradation follows pseudo-first-order kinetics, with a minimum degradation rate between pH 4.5 and 5.5. Below pH 2.0, acid-catalyzed β-lactam ring opening dominates. Above pH 8.0, the primary amine of L-arginine can participate in aminolysis of the β-lactam carbonyl, producing a discolored solution and measurable potency loss. The L-arginine stoichiometry of 725 mg per 1.0 g cefepime base is therefore not an inert filler; it determines the ionic strength and buffer capacity after reconstitution. Reconstitution diluents listed in the regulatory label include Sterile Water for Injection, 0.9% Sodium Chloride Injection, and 5% Dextrose Injection. Admixture compatibility data in the labeling support storage of constituted solutions at 25°C for 24 hours or at 2–8°C for 7 days, provided that the nominal concentration is maintained within the labeled range and the container closure system remains intact. When the pH of the reconstituted solution falls below 4.0 or rises above 6.0, the specification is considered out-of-range and the lot is rejected because accelerated hydrolytic degradation cannot be ruled out by appearance alone.

Sterile API production is typically conducted in jacketed glass-lined reactors equipped with a high-torque stainless-steel anchor impeller operating at 30–50 rpm. Salt formation is carried out at 10–15°C, followed by sterile filtration through 0.22 µm PVDF membrane filters into an ISO 5 filling zone. Anti-solvent crystallization is initiated under continuous agitation; uncontrolled jacket cooling can produce batch-to-batch variation in L-arginine co-crystallization stoichiometry. A cooling ramp of 0.5°C/min is often specified to limit this variability. The wet cake is dried in a vacuum tray dryer at 35°C and 5 kPa for approximately 18 hours, achieving residual water below 3.5%. Equipment qualification follows ASTM E2500 principles and cleaning validation is performed by swab sampling with HPLC-MS analysis to demonstrate carryover below 1 ppm of the previous product. Aseptic crystallization is used because terminal steam sterilization of the dry powder is not feasible for beta-lactam antibiotics; the β-lactam ring undergoes thermal degradation at autoclave temperatures above 121°C.

Pelletization Constraints for Enteric-Coated Oral Granule Dosage Forms

For oral tablet, capsule, or granule development, two process barriers are encountered with the cefepime hydrochloride and L-arginine combination. First, L-arginine is hygroscopic; at relative humidity above 60% RH, powder tack increases and adhesion to high-shear granulator bowl surfaces is observed. Second, wet granulation with aqueous binder causes localized pH shifts above 6.5, accelerating cefepime base hydrolysis and producing sedimentable degradation products. Published human pharmacokinetic data for oral cefepime efficacy are limited; the molecule exhibits negligible oral bioavailability due to gastric acid degradation and poor intestinal permeability. Therefore, solid oral dosage development is not supported by current clinical evidence, and the oral route should be considered exploratory. If dry granulation is attempted, roller compaction with knurled rolls and a roll gap of 1.5–2.0 mm is preferable to wet granulation. Non-aqueous granulation using isopropanol requires drying to the ICH Q3C limit for isopropanol, which is 50 mg/day permitted daily exposure. For any enteric-coated pellet formulation, dissolution testing per USP <711> Apparatus 1 at 100 rpm in 0.1 N HCl for 2 hours followed by pH 6.8 phosphate buffer is used to assess coating integrity; however, no pharmacopoeial monograph exists for oral cefepime solid dosage forms, and specification limits must be justified case-by-case.

Injectable-grade material requires particulate matter testing under USP <788>. After reconstitution with 10 mL of diluent, the solution must meet the limit of not more than 6,000 particles ≥ 10 µm and not more than 600 particles ≥ 25 µm per container by light obscuration particle size analysis. The L-arginine component must meet the USP L-Arginine monograph; the specific rotation of L-arginine is specified between +26.3° and +27.7° (c=8, 6 N HCl) and loss on drying is not more than 0.5%. Container closure integrity is verified by dye ingress testing according to USP <1207>. During filling of sterile powder into vials, environmental monitoring in the ISO 5 zone includes active air sampling at 1 m³ per location and settle plates exposed for 4 hours. The maximum permitted viable count per ISO 5 surface is 1 CFU per contact plate. These controls are required because the product is destined for parenteral administration, where the absence of sterility and endotoxin burden is a release criterion rather than a process capability indicator.

When the L-Arginine Stoichiometric Ratio Deviates from the Labeled 0.725

The label ratio of 725 mg L-arginine per 1.0 g cefepime base is critical for maintaining the reconstituted pH. If L-arginine content drops below 90% of label claim, the reconstituted solution pH falls below 4.0, increasing injection site pain and shortening the acceptable hold time of the constituted solution. If L-arginine exceeds 110% of label claim, the pH approaches 6.5–7.0, where base-catalyzed hydrolysis of the β-lactam ring accelerates and the solution takes on an amber discoloration. Production records from lyophilized presentations demonstrate that controlling the L-arginine assay to 95.0%–105.0% of label claim reduces reconstitution pH variation to ±0.3 pH units. This level of control is achieved through in-process pH monitoring during salt formation and through paired HPLC assay of both cefepime and L-arginine on each bulk batch before filling. A batch with L-arginine content below the lower release limit cannot be corrected by simple addition of L-arginine at the filling stage, because the homogeneity of the dry blend cannot be guaranteed without an additional validated blending step.

Compared with ceftazidime formulated with sodium carbonate, cefepime hydrochloride with L-arginine provides a broader Gram-negative spectrum including Pseudomonas aeruginosa and is more stable against AmpC β-lactamase-producing organisms; however, published data for specific clinical indication equivalence are limited. Ceftazidime pentahydrate requires sodium carbonate at approximately 118 mg per 1 g ceftazidime to achieve solubility, which introduces a sodium load per vial. Cefepime hydrochloride with L-arginine does not contain sodium, a difference relevant for patients on sodium-restricted regimens. Compared with ceftriaxone disodium, the L-arginine formulation is not associated with calcium-ceftriaxone particulate precipitation. Ceftriaxone labeling contraindicates concurrent administration with calcium-containing solutions in neonates because of the risk of particulate precipitation in the lungs and kidneys; this contraindication does not apply to cefepime hydrochloride with L-arginine. These differences are established in regulatory label information and are not formulation-specific promotional claims requiring additional clinical validation.

Residual Solvent Limits Imposed by ICH Q3C on the Hydrochloride Salt

The hydrochloride salt is crystallized and dried from solvent systems that commonly include acetone, isopropanol, ethyl acetate, and occasionally methanol. ICH Q3C classifies methanol as Class 2 with a permitted daily exposure of 30 mg/day, acetone as Class 3 with a permitted daily exposure of 50 mg/day, and isopropanol as Class 3. Ethyl acetate is Class 3. For parenteral products, the concentration limit for a Class 3 solvent is 0.5% when the daily dose is 10 g or less. For the cefepime hydrochloride with L-arginine API, the manufacturing process is designed to eliminate Class 1 solvents entirely; benzene, carbon tetrachloride, and 1,2-dichloroethane must not be detected above the ICH Q3C specified limits of 2 ppm, 4 ppm, and 5 ppm, respectively. Residual solvent testing is performed by headspace gas chromatography with flame ionization detection and is included in both batch release and stability protocols. The limit for acetone in the final dried powder is commonly set at not more than 500 ppm when justified by the maximum daily dose of cefepime, which is 6 g/day in severe infections. Published data for this specific formulation configuration is limited; therefore, vendor-specific solvent data and a residue risk assessment per ICH Q3C are required before assigning final release limits.

The sterile API is stored in hermetically sealed Type I borosilicate glass vials with bromobutyl rubber stoppers under nitrogen overlay. Storage temperature is controlled at 2–8°C; excursions above 25°C for more than 48 hours initiate color change from white to pale yellow, an early indicator of oxidative degradation at the N-methylpyrrolidine side chain. The material must not be combined with aminoglycosides in the same admixture container due to physical incompatibility and potential precipitation at pH above 7.5. Pre-drying is not required for aseptic compounding if water content remains below 3.5%; however, dry powder blending for oral dosage forms should proceed only when relative humidity is held below 40% RH and mixing time in a V-blender is limited to 15 minutes at 15 rpm to avoid electrostatic adherence to stainless steel surfaces.